Development of next generation transdermal vaccine for cancer treatment

2016 Fiscal Year Final Research Report

• Project/Area Number: 26430176
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Tumor therapeutics
• Research Institution: Kurume University
• Principal Investigator: YAMADA Akira 久留米大学, 先端癌治療研究センター, 教授 (50158177)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: がん / 免疫療法 / がんワクチン / アジュバント / 腫瘍 / 経皮免疫 / ペプチドワクチン

Outline of Final Research Achievements

Freund’s incomplete adjuvant, one of the most popularly used adjuvant for cancer vaccines, has several adverse effects such as long term retention and an induction of inflammation at the injection site. We attempted to develop a next generation of transdermal vaccine for cancer treatment with no or low such adverse effects. We found that glycyrrhizin augmented vaccine-induced immune response with transdermal adjuvant, and the augmenting effect of glycyrrhizin was also observed in other synthetic HMGB1 inhibitors. Thus the effects are common to the HMGB1 inhibitors. In a therapeutic vaccine model, glycyrrhizin inhibited the growth of transplanted tumors. These findings might be valuable for further development of transdermal vaccines.

Free Research Field

腫瘍免疫学、がん免疫療法